Identification of microbiota-specific mucosal immune responses driving primary sclerosing cholangitis (PSC) and concomitant inflammatory bowel disease (IBD).<br> - Understanding PSC-IBD

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 250 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

暂无简介。

•-Diagnosis of PSC according to generally accepted criteria (EASL diagnostic guidelines): presence of elevated serum markers of cholestasis (ALP, GGT) not otherwise explained, when MRCP or ERCP show characteristic bile duct changes with multifocal strictures and segmental dilatations, and causes of secondary sclerosing cholangitis and other cholestatic disorders are excluded;
•-IBD (CD, UC or indeterminate colitis) confirmed by clinical evaluation in combination with endoscopic and histological investigations;
•-Informed consent by patients or, when applicable, parents.

•-Diagnosis of immunodeficiency syndromes;
•-Secondary causes of sclerosing cholangitis;
•-Evidence of decompensated liver disease such as previous variceal bleeding, ascites, or hepatic encephalopathy;
•-Anticipated need for liver transplantation within one year; after liver transplantation these patients will be eligible again.
•-Findings highly suggestive of liver disease of an alternative or concomitant etiology, such as alcoholic liver disease, hepatitis B or C, haemochromatosis, Wilson*s disease, a1-antitrypsin deficiency, non-alcoholic steatohepatitis, primary biliary cirrhosis;
•-Pregnant or lactating patients;
•-Active illicit drug or alcohol abuse;
•-Suspicion of ascending cholangitis or acute (septic) cholangitis or one of these events in the previous 6 months;
•-Any infection necessitating antibiotics use >14 days in the previous 6 months.

发起方